Grace Therapeutics, Inc. (GRCE)
Nasdaq: GRCE · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 2008
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in March.| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Period ending | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 |
| Report filed | Jun 18, 2026 | Jun 23, 2025 | Jun 21, 2024 | Jun 23, 2023 | Jun 21, 2022 | Jun 22, 2021 | Jun 29, 2020 | Jun 26, 2019 | Jun 29, 2018 |
| Revenue | · | · | · | · | 0 | 196 | · | · | · |
| Cost of revenue | · | · | · | · | 0 | 76 | · | · | · |
| Research and development | 2,405 | 9,511 | 4,683 | 9,972 | 5,559 | 4,173 | 15,974 | 29,373 | · |
| Sales and marketing | · | · | 252 | 661 | 518 | 1,142 | 2,665 | 494 | · |
| General and administrative | 8,672 | 7,168 | 6,684r | 7,614 | 9,263 | 5,521 | 5,799 | 4,539 | · |
| Operating income | -11,077 | -16,679 | -12,852 | -52,155 | -15,589 | -16,419 | -24,438 | -34,406 | · |
| Interest and investment income | 685 | 711 | 911 | 246 | 77 | 107 | 336 | 358 | · |
| Total non-operating income (expense) | 1,584 | 3,912 | -1,833 | 184 | 5,122 | -3,259 | -1,075 | -4,960 | · |
| Income before income taxes | -9,493 | -12,767 | -14,685 | -51,971 | -10,467 | -19,678 | -25,513 | -39,366 | · |
| Income tax expense | -1,700 | -3,199 | -1,832 | -9,542 | -648 | 0 | 0 | 0 | · |
| Net income | -7,793 | -9,568 | -12,853 | -42,429 | -9,819 | -19,678 | -25,513 | -39,366 | · |
| Earnings per share, basic | -0.47 | -0.79 | -1.35 | -5.71r | -1.62b | · | · | · | · |
| Earnings per share, diluted | -0.47 | -0.79 | -1.35 | -5.71r | -1.62b | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.62b | -7.98rb | -1.80b | -4.38b | · |
| Weighted average shares, basic | 16,510,632 | 12,087,270 | 9,529,123 | 7,435,472r | 6,140,294b | · | · | · | · |
| Weighted average shares, diluted | 16,510,632 | 12,087,270 | 9,529,123 | 7,435,472r | 6,140,294b | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 6,140,294b | 2,471,372rb | 14,096,961b | 9,048,382b | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-6 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted